INVO Fertility reported third-quarter 2025 revenue of $1.76 million, up 23% year over year, with consolidated clinic revenue from its Atlanta and Madison sites rising 21%. Revenue across all clinics, including equity-method locations, reached $2.0 million, up 18%. Despite top-line momentum, the company’s net loss widened to $2.6 million, partly reflecting financing-related charges, while adjusted EBITDA remained essentially flat at a loss of about $0.95 million. INVO also highlighted a 130% year-over-year increase in revenue from its INVOCELL device, alongside continued clinic expansion initiatives, telehealth reach, and operational efficiency moves such as integrating an AI-powered scribe.
The strategic question is whether a dual model—owning clinics while commercializing a differentiated device-enabled procedure—can carve out a meaningful share in a consolidating fertility landscape. The device-led intravaginal culture approach promises lower-cost, more connected care than traditional IVF, yet the financials underscore the scale challenge: clinic growth is real but small in absolute terms, and device sales, while accelerating, start from a modest base. The near-term thesis hinges on converting policy tailwinds and workflow efficiencies into payer-backed demand and clinic-level margin expansion.
Timing matters. A recent federal policy update enabling employers to offer standalone infertility benefits, including IVF, could expand coverage beyond today’s patchwork of carve-outs and cash-pay models. If employers adopt these benefits at scale, patient volumes may shift from out-of-pocket to reimbursed pathways, changing price sensitivity and potentially compressing cash-pay premiums across the category. That dynamic would favor providers with credible cost-of-care advantages and standardized protocols. For patients, expanded benefits could unlock access earlier in the treatment journey. For payers and benefits managers, it raises the bar for clinical and economic evidence to differentiate new modalities such as intravaginal culture from IVF and IUI.
For competitors—clinic roll-ups, benefit platforms, and device innovators—the signal is clear: the next growth phase in fertility will be won by those who align clinical innovation with employer-driven financing mechanisms. Players like INVO that own points of care can embed devices and protocols, control patient experience, and generate real-world evidence at the clinic level. But scale players with broader networks and established employer relationships may move faster to capture newly covered lives. The race will be about contracting sophistication, throughput, and outcomes visibility as much as it is about brand.
Medical Affairs will be central. Widespread payer acceptance of intravaginal culture will require rigorous, contemporary RWE on live birth rates, safety, time-to-pregnancy, and total cost of care versus IVF and IUI, across diverse patient populations. Standardized training for embryology and clinical teams, already a focus for INVOCELL, must be paired with data capture in routine practice. Operational steps like AI-driven documentation can support throughput and guideline adherence, but the differentiator for reimbursement will be outcomes and economics, not workflow alone.
The inflection to watch over the next year is whether employer benefit adoption accelerates and whether INVO can translate that tailwind into contracts, clinic acquisitions, and measurable unit economics. If reimbursement expands and intravaginal culture proves cost-effective at scale, could fertility finally shift from premium cash-pay to a value-managed specialty line—and who will own the formulary-like power in this new benefit class?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
